Loading clinical trials...
Loading clinical trials...
A Multi-center, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of CSJ148 Compared to Placebo to Prevent Human Cytomegalovirus (HCMV) Replication in Stem Cell Transplant Patients
Conditions
Interventions
CSJ148
Placebo
Locations
17
United States
Novartis Investigative Site
San Francisco, California, United States
Novartis Investigative Site
Gainesville, Florida, United States
Novartis Investigative Site
Beech Grove, Indiana, United States
Novartis Investigative Site
Durham, North Carolina, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
Leuven, Belgium
Start Date
June 2, 2015
Primary Completion Date
December 7, 2016
Completion Date
December 7, 2016
Last Updated
January 5, 2021
NCT03369912
NCT01063829
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions